Related Experiment Video
Updated: Sep 3, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer
Volkmar Müller1, Manfred Welslau2, Diana Lüftner3
1Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
Abstract:
For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer. Some of these substances have now been approved for use in the early stages of the disease, or are expected to be approved in the near future, so the therapeutic landscape will change once again. Therefore, current scientific efforts are focused on the introduction of new substances and understanding their mechanisms of progression and efficacy. This review summarizes recent developments with reference to recent publications and conferences. Findings on the treatment of patients with HER2-positive breast cancer and brain metastases are presented, as are a number of studies looking at biomarkers in patients with HER2-negative, hormone receptor-positive breast cancer. In particular, the introduction of oral selective estrogen receptor degraders provides new opportunities to establish biomarker-based therapy. Molecular diagnostics is establishing itself as a diagnostic marker and parameter of progression.
Insights
Novel therapies, including CDK4/6 inhibitors and antibody-drug conjugates, are transforming advanced breast cancer treatment. Research now focuses on new agents, biomarker-based strategies, and early-stage applications for improved patient outcomes.
Area of Science:
- Oncology
- Medical Therapeutics
- Clinical Research
Background:
- Advanced breast cancer treatment has seen significant advancements with novel therapies.
- Emerging treatments include CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, and targeted agents like alpelisib, tucatinib, trastuzumab-deruxtecan, and sacituzumab-govitecan.
- These therapies are expanding beyond advanced stages, with some moving into early-stage disease treatment.
Purpose of the Study:
- To review recent developments in advanced breast cancer therapeutics.
- To summarize findings on HER2-positive breast cancer, including brain metastases.
- To highlight the role of biomarkers and molecular diagnostics in HER2-negative, hormone receptor-positive breast cancer therapy.
Main Methods:
- Review of recent scientific publications and conference presentations.
- Analysis of clinical data on novel therapeutic agents.
- Examination of biomarker studies in specific breast cancer subtypes.
Main Results:
- Novel therapies have substantially altered the treatment landscape for advanced breast cancer.
- Specific findings are presented for HER2-positive breast cancer with brain metastases.
- Biomarker-driven approaches, particularly with oral selective estrogen receptor degraders, show promise for hormone receptor-positive breast cancer.
Conclusions:
- The therapeutic landscape for advanced breast cancer is rapidly evolving with new drug approvals and expanded indications.
- Molecular diagnostics and biomarker-based therapies are becoming increasingly crucial for personalized treatment strategies.
- Ongoing research focuses on understanding the efficacy and mechanisms of novel agents to further improve patient care.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistant Cancers
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...